Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Molecular biology reports
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/39797940/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- CRISPR detection of cardiac tumor-associated microRNAs. Fu, Youlin Zhang, Peng Chen, Feng Xie, Ziqiang Xiao, Shihui Huang, Zhihao Lau, Cia-Hin Zhu, Haibao Luo, Jun Humans MicroRNAs Heart Neoplasms CRISPR-Cas Systems Myxoma Hemangiosarcoma Biomarkers, Tumor As multiple imaging modalities cannot reliably diagnose cardiac tumors, the molecular approach offers alternative ways to detect rare ones. One such molecular approach is CRISPR-based diagnostics (CRISPR-Dx). CRISPR-Dx enables visual readout, portable diagnostics, and rapid and multiplex detection of nucleic acids such as microRNA (miRNA). Dysregulation of miRNA expressions has been associated with cardiac tumors such as atrial myxoma and angiosarcoma. Diverse CRISPR-Dx systems have been developed to detect miRNA in recent years. These CRISPR-Dx systems are generally classified into four classes, depending on the Cas proteins used (Cas9, Cas12, Cas13, or Cas12f). CRISPR/Cas systems are integrated with various isothermal amplifications to detect low-abundance miRNAs. Amplification-free CRISPR-Dx systems have also been recently developed to detect miRNA directly. Herein, we critically discuss the advances, pitfalls, and future perspectives for these CRISPR-Dx systems in detecting miRNA, focusing on the diagnosis and prognosis of cardiac tumors.